Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?
- PMID: 34865692
- DOI: 10.1016/j.beha.2021.101335
Can venetoclax-based therapy replace 7+3 induction in fit older adults with AML?
Abstract
Older patients with acute myeloid leukemia (AML) face a dismal prognosis. Although venetoclax-based therapy has led to improved outcomes among unfit older patients with AML, it is not curative and its efficacy and long-term outcomes among fit older patients is unclear. This review provides insights into factors that influence treatment choices among older patients with AML and what we would need to know for venetoclax-based therapy to replace standard intensive 7 + 3 induction therapy.
Keywords: 7+3; AML; Acute myeloid leukemia; Azacytidine; CR; Complete remission; Intensive chemotherapy; OS; Overall survival; Venetoclax.
Copyright © 2021. Published by Elsevier Ltd.
Similar articles
-
Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.Future Oncol. 2021 Aug;17(23):2989-3005. doi: 10.2217/fon-2021-0262. Epub 2021 May 24. Future Oncol. 2021. PMID: 34024158 Review.
-
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.Am J Hematol. 2021 Jul 1;96(7):790-795. doi: 10.1002/ajh.26190. Epub 2021 Apr 29. Am J Hematol. 2021. PMID: 33836555
-
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.Ann Hematol. 2022 Feb;101(2):379-387. doi: 10.1007/s00277-021-04693-8. Epub 2021 Oct 9. Ann Hematol. 2022. PMID: 34628534
-
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol. 2020 Oct;7(10):e724-e736. doi: 10.1016/S2352-3026(20)30210-6. Epub 2020 Sep 5. Lancet Haematol. 2020. PMID: 32896301 Free PMC article. Clinical Trial.
-
Mechanisms for resistance in AML insights into molecular pathways mediating resistance to venetoclax.Best Pract Res Clin Haematol. 2021 Mar;34(1):101251. doi: 10.1016/j.beha.2021.101251. Epub 2021 Feb 6. Best Pract Res Clin Haematol. 2021. PMID: 33762105 Review.
Cited by
-
Feasibility of allogeneic stem cell transplantation (HSCT) in patients with acute myeloid leukemia previously treated with CPX-351: report from a single center.Ann Hematol. 2025 Jul;104(7):3855-3861. doi: 10.1007/s00277-025-06462-3. Epub 2025 Jun 23. Ann Hematol. 2025. PMID: 40549144 Free PMC article.
-
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.Blood Cancer J. 2022 Nov 9;12(11):151. doi: 10.1038/s41408-022-00747-w. Blood Cancer J. 2022. PMID: 36347832 Free PMC article.
-
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.Blood Cancer J. 2022 Jul 11;12(7):107. doi: 10.1038/s41408-022-00700-x. Blood Cancer J. 2022. PMID: 35821023 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
